RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Prader-Willi Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Sleeve gastrectomy in pediatric and transition age patients with Prader-Willi syndrome: a 5-year longitudinal study.
Aureli Alessia et al., The Journal of clinical endocrinology and metabolism (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42178926/
- 2.
Treatment of hyperphagia and obesity in Prader-Willi syndrome.
Höybye Charlotte et al., Journal of internal medicine (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42881496/
- 3.
HIỆU QUẢ LIỆU PHÁP HORMON TĂNG TRƯỞNG TÁI TỔ HỢP Ở TRẺ MẮC HỘI CHỨNG PRADER-WILLI TẠI BỆNH VIỆN NHI TRUNG ƯƠNG
Đào Hoàng Anh et al., Tạp chí Nhi khoa (14 October 2026)
https://doi.org/10.52724/tcnk.v19i4.552
- 4.
SMCHD1 is a target for gene activation therapy to treat Prader-Willi syndrome.
Iminitoff Megan et al., Science advances (9 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42853925/
- 5.
From iPSC disease modeling to epigenome editing: Toward therapeutic reversal of genomic imprinting disorders.
Nemoto Akisa et al., Neuroscience research (9 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42854759/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464 · Recruiting · Phase 3 · Harmony Biosciences Management, Inc.
Ages 6 and over
https://clinicaltrials.gov/study/NCT06366464
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Prader-Willi Syndrome
Prader-Willi syndrome is a complex genetic condition caused by loss of function of genes on chromosome 15. It causes hyperphagia (insatiable hunger), intellectual disability, and hormonal problems. Without strict dietary management, obesity and its complications are a major risk. Growth hormone therapy has been transformative.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
OBJECTIVE: To evaluate the long-term effectiveness of laparoscopic sleeve gastrectomy (LSG) in pediatric and transition age patients with Prader-Willi syndrome (PWS). DESIGN: Single-center, longitudinal, retrospective cohort study. METHODS: We reviewed the electronic health records of 110 patients with PWS and 268 subjects undergoing LSG. We included 16 patients with PWS and severe obesity (PWS-LSG) and 32 matched non-syndromic patients with obesity (OB-LSG), both undergoing LSG, and 16 patients with PWS receiving lifestyle intervention only (PWS-LS). The primary endpoint was ΔBMI-SDS% at 5 years. RESULTS: In PWS-LSG, BMI-SDS decreased from 5.18 to an early nadir at 1-2 years (median ΔBMI-SDS% ∼-26%), then partially rebounded to 4.75 at 5 years, with ΔBMI-SDS% -16.9% (P = .012). Conventional metrics confirmed this attenuated response, with %BMI change -2.8% and absolute ΔBMI-SDS -1.10 at 5 years. In OB-LSG, BMI-SDS declined from 4.95 to 2.24, with larger and more sustained improvement (ΔBMI-SDS% -57.4%; P < .001 within-group; P = .002 vs PWS-LSG), corresponding to a %BMI change -40.1% and absolute ΔBMI-SDS -2.81 at 5 years. In PWS-LS, BMI-SDS increased from 2.25 to 3.19 (ΔBMI-SDS% + 36.4%, P = .003). The mean number of obesity-related comorbidities decreased in PWS-LSG (2.69 ± 1.66 to 1.94 ± 1.18; P = .041) and in OB-LSG (1.25 ± 0.88 to 0.56 ± 0.76; P < .001), but increased in PWS-LS (1.56 ± 0.96 to 2.44 ± 1.32; P = .004). CONCLUSION: In PWS, LSG produces clinically relevant early weight loss with partial maintenance at 5 years, but markedly attenuated long-term benefit compared with non-syndromic peers. Nevertheless, when interpreted against the progressive worsening of obesity and cardiometabolic comorbidities observed with lifestyle intervention alone, LSG appears to modify disease trajectory in PWS.
Common Questions
What is Prader-Willi Syndrome?
Prader-Willi syndrome is a complex genetic condition caused by loss of function of genes on chromosome 15. It causes hyperphagia (insatiable hunger), intellectual disability, and hormonal problems. Without strict dietary management, obesity and its complications are a major risk. Growth hormone therapy has been transformative.
How many clinical trials are available for Prader-Willi Syndrome?
RareWays currently indexes 101 clinical trials for Prader-Willi Syndrome, of which 9 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Prader-Willi Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Prader-Willi Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.